Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Gains 7%; BSE HEALTHCARE Index Up 0.4%
Mon, 23 Sep 10:33

Glenmark Pharma Gains 7%; BSE HEALTHCARE Index Up 0.4%Image source: Eoneren/www.istockphoto.com

Glenmark Pharma share price has zoomed 7% and is presently trading at Rs 1,742.5.

Meanwhile, the BSE HEALTHCARE index is at 44,307.6 (up 0.4%).

Among the top gainers in the BSE HEALTHCARE index today are METROPOLIS HEALTHCARE (up 3.1%) and SUVEN PHARMACEUTICALS (up 2.3%).

ERIS LIFESCIENCES (down 2.2%) and Natco Pharma (down 1.7%) are among the top losers today.

Over the last one year, Glenmark Pharma has moved up from Rs 856.5 to Rs 1,742.5, registering a gain of Rs 886.0 (up 103.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,349.9 to 44,307.6, registering a gain of 56.3% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 178.1%), SUVEN PHARMACEUTICALS (up 129.0%) and Glenmark Pharma (up 103.5%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 84,743.4 (up 0.2%).

The top gainers among the BSE Sensex today are SBI (up 1.7%) and M&M (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 25,891.9 (up 0.4%). ONGC and BPCL are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 66,800.8 to 84,743.4, registering a gain of 17,942.6 points (up 26.9%).

Glenmark Pharma Financial Update...

Glenmark Pharma net profit grew 803.0% YoY to Rs 3,402 million for the quarter ended June 2024, compared to a profit of Rs 377 million a year ago. Net sales rose 6.9% to Rs 32,442 million during the period as against Rs 30,361 million in April-June 2023.

For the year ended March 2024, Glenmark Pharma reported 1944.2% decrease in net profit to Rs -18,309 million compared to net loss of Rs 896 million during FY23. Revenue of the company grew 2.0% to Rs 118,131 million during FY24.

The current Price to earnings ratio of Glenmark Pharma, based on rolling 12 month earnings, stands at -32.2.


Equitymaster requests your view! Post a comment on "Glenmark Pharma Gains 7%; BSE HEALTHCARE Index Up 0.4%". Click here!